NCT00284986View on ClinicalTrials.gov

Safety and Efficacy of Prochymal® for the Salvage of Treatment-Refractory Acute GVHD Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

November 18, 2005

Primary Completion Date

April 25, 2006

Study Completion Date

February 8, 2007

Conditions

Graft Versus Host Disease

Interventions

DRUG

Prochymal®

Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells

Trial Locations (1)

27708

Duke University, Durham

Sponsors

Lead Sponsor

Mesoblast, Inc.

All Listed Sponsors

lead

Mesoblast, Inc.

INDUSTRY

NCT00284986 - Safety and Efficacy of Prochymal® for the Salvage of Treatment-Refractory Acute GVHD Patients | Biotech Hunter | Biotech Hunter